Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury


Study design

Retrospective chart study.


The aim was to examine continuation of treatment of individuals with spinal cord injury including myelomeningocele and neurogenic detrusor overactivity, treated with repeated intra-detrusor Botulinum toxin A injections, and to investigate factors associated with discontinuation of treatment.


Rigshospitalet, Denmark


This study included 128 individuals with spinal cord injury and neurogenic detrusor overactivity, who were offered repeated Botulinum toxin A injections between 2001 and 2018. Continuation rates of the treatment were estimated using Kaplan Meier analysis. A Cox proportional hazard analysis was used to investigate factors predictive of discontinuation.


A total of 1156 treatments were performed. The median number of treatments was six (IQR 9, range 1−51), and median follow-up was 10.6 years (IQR 8.5, range 0−16.9). All urodynamic parameters changed significantly after the first treatment (p < 0.001). The continuation group had significantly higher mean maximum bladder capacity after the first injections compared with the discontinuation group, with a mean difference between the groups of 84.5 mL (95% CI 4.7–164.2) (p = 0.038). The probability of continuing treatments after 5 years was 59% (95% CI 50.0–67.8) and 50% (95% CI 40.1–59.3) after 10 years. Individuals aged 31–50 years were more likely to continue treatment compared with those aged >50 years (95% CI 0.21‒0.79) (p = 0.008). No other factors predicted discontinuation.


This long-term follow-up study showed that 50% of people with spinal cord injury starting intra-detrusor Botulinum toxin A for neurogenic detrusor overactivity are still receiving injections after 10 years.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.


  1. 1.

    Nseyo U, Santiago-lastra Y. Long-term complications of the neurogenic bladder. Urol Clin North Am. 2017;44:355–66.

    Article  Google Scholar 

  2. 2.

    Gormley EA. Urologic complications of the neurogenic bladder. Urol Clin North Am. 2010;37:601–7.

    Article  Google Scholar 

  3. 3.

    Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil. 2001;80:916–22.

    CAS  Article  Google Scholar 

  4. 4.

    Blok B, Pannek J, Castro-Diaz D, Del Popolo G, Groen J, Hamid R et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018.

  5. 5.

    Schurch B, Stöhrer G, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum toxin-A for treating detrusor hyperreflexia in spinal cord injured patientpt 1s: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164(3 Pt 1):692–7.

    CAS  Article  Google Scholar 

  6. 6.

    Goessaert A, Everaert K. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis. Exp Rev Neurother. 2012;12:763–75.

    CAS  Article  Google Scholar 

  7. 7.

    Bagi P, Biering-Sørensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol. 2004;38:495–8.

    CAS  Article  Google Scholar 

  8. 8.

    Kirshblum SC, Burns SP, Biering-Sorensen F, Donovan W, Graves DE, Jha A, et al. Reference for the 2011 revision of the international standards for neurological classification of spinal cord injury. J Spinal Cord Med. 2011;34:547–54.

    Article  Google Scholar 

  9. 9.

    Frankel HL, Hancock DO, Hyslop G, Melzak J, Michaelis LS, Ungar GH, et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. Paraplegia 1969;7:179–92.

    CAS  PubMed  Google Scholar 

  10. 10.

    Biering-Sørensen F, DeVivo MJ, Charlifue S, Chen Y, New PW, Noonan V, et al. International Spinal Cord Injury Core Data Set (version 2.0)—including standardization of reporting. Spinal Cord 2017;55:759–64.

    Article  Google Scholar 

  11. 11.

    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49.

    Article  Google Scholar 

  12. 12.

    Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742–50.

    CAS  Article  Google Scholar 

  13. 13.

    Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012;187:2131–9.

    CAS  Article  Google Scholar 

  14. 14.

    Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013;111:106–13.

    CAS  Article  Google Scholar 

  15. 15.

    Leitner L, Guggenbühl-Roy S, Knüpfer SC, Walter M, Schneider MP, Tornic J, et al. More than 15 years of experience with intradetrusor onabotulinumtoxina injections for treating refractory neurogenic detrusor overactivity: lessons to be learned. Eur Urol 2016;70:522–8.

    CAS  Article  Google Scholar 

  16. 16.

    Joussain C, Popoff M, Phé V, Evan A, Bosset PO, Pottier S, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn 2018;37:799–806.

    CAS  Article  Google Scholar 

  17. 17.

    Veeratterapillay R, Harding C, Teo L, Vesdev N, Abroaf A, Dorkin TJ, et al. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int J Urol. 2014;21:175–8.

    CAS  Article  Google Scholar 

  18. 18.

    Rahnama’i MS, Marcelissen TAT, Brierley B, Schurch B, de Vries P. Long-term compliance and results of intravesical botulinum toxin A injections in male patients. Neurourol Urodyn 2017;36:1855–9.

    Article  Google Scholar 

  19. 19.

    Biering-Sørensen F, Craggs M, Kennelly M, Schick E, Wyndaele JJ. International lower urinary tract function basic spinal cord injury data set. Spinal Cord 2008;46:325–30.

    Article  Google Scholar 

Download references

Author information




KPH was responsible for collecting data, analyzing and interpreting data, and writing the report. NK was responsible for designing the protocol, contributed to analyzing and interpreting data, and revised the article critically. PB and FBS was responsible for designing the protocol, interpreting data, and revised the article critically. ME was responsible for designing and writing the protocol, interpreted and analyzed the data, conducted the Cox proportional Hazard analysis, and revised the article critically.

Corresponding author

Correspondence to Katrine P. Hebert.

Ethics declarations

Ethical approval

The study was approved by the Danish data protection agency and the Danish patient safety authority. We certify that all applicable institutional and governmental regulations concerning the ethical use of data originally collected for clinical purposes were followed during the course of this research.

Conflict of interest

NK and KPH have received travel grants from Contura. ME has received honoraria and travel grants from Contura. However, Contura had no involvement in the collection, analysis, interpretation, or write up of this paper. PB and FBS have no disclosures to declare.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hebert, K.P., Klarskov, N., Bagi, P. et al. Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord 58, 675–681 (2020).

Download citation

Further reading


Quick links